Integrity Capital Management (HK)’s Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 FPAC.WS Stock Holding History
Bought
Maintained
Sold
Other funds holding FPAC.WS
PWAM
AC
LP
TP
DKCM
MF
Integrity Capital Management (HK)'s FPAC.WS Position: Q1 2022 in Review
Integrity Capital Management (HK) sold out of Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 (FPAC.WS) in Q1 2022, closing a stake of 14,016 shares — an estimated $28K sold.
Integrity Capital Management (HK) first reported a position in FPAC.WS in Q4 2021 and held it in 1 quarter. The position peaked at $28K in Q4 2021. 29 funds tracked by Wall St. Rank hold FPAC.WS as of Q1 2022.
- Integrity Capital Management (HK) reported no remaining Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position as of Q1 2022 after selling out during the quarter.
- Integrity Capital Management (HK) sold 14,016 Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 shares in Q1 2022, an estimated $28K.
- Integrity Capital Management (HK) first reported a position in Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 in Q4 2021 and held it in 1 quarter.
- Integrity Capital Management (HK)'s Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position peaked at $28K in Q4 2021.
- 29 funds tracked by Wall St. Rank held Far Peak Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 as of Q1 2022.
Based on Integrity Capital Management (HK)'s 13F filing for Q1 2022, filed 26 Apr 2022.